GENERICOS: "Generando" conciencia (V) Y lo que viene...

Y Capgemini , en su informe Life Sciences: Performing in the Downturn and Beyond considera los genéricos como una alternativa de mercado en el futuro...




(*)
(*)

Impact of the innovation/patent
loss imbalance dampens growth prospects.

Consistent with trends of the past several years, the next five are expected to reflect a significant imbalance between new product introductions and patent losses. This is the primary factor limiting global pharmaceutical market growth to the mid-single digits through 2013. During the next five years, products that currently generate an unprecedented $137 billion in sales are expected to face generic competition, including Lipitor^®, Plavix^®, and Seretide^®. At the same time, new products that will enable innovative approaches for treating patients suffering from diseases such as osteoporosis, respiratory ailments, thrombosis, multiple sclerosis and cancer are not expected to generate the same magnitude of sales as products losing patent protection.


Y las proyecciones de IMS lo ratifican al considerar las "perdidas" de derecho de patente en los años próximos... (Ver)


Ver anteriores


(*) De la presentación hecha en el Seminario Internacional "Hacia una política Integral en materia de medicamentos" organizado por ANAFAM (México 30/XI/2009)